entertainment -WSS

entertainment

author：Wikipedia 2025-10-02 23:44:56 - browse：1

Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing.

Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. At a meeting at Cold Spring Harbor Laboratory that drew more than 400 of the field’s top scientists, the company shared more detailed information about studies it has conducted to assess the risks that renegade CRISPR components could be getting into an egg or sperm. These studies demonstrate “that there’s no evidence of vertical germline transmission of those edits,” Jonathan Phillips, head of pharmacology and toxicology at Intellia, said during a presentation Saturday.

Intellia is one of the leading companies working to advance in vivo gene editing therapies. In a landmark study published in the New England Journal of Medicine in 2021, Intellia revealed data from six patients in its trial for a transthyretin amyloidosis therapy — showing for the first time that it was possible to precisely alter the DNA of particular cells within the human body to treat disease with a one-time infusion of CRISPR. Included in the supplementary material was a redacted version of the company’s package requesting authorization to start its clinical trial. It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in organs other than the liver, including the spleen and adrenal glands. In three out of 12 female monkeys, they also found editing in the animals’ ovaries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Medicare Advantage plans can’t deny care with AI, CMS warns

WSS

Why Novartis is going to walk from its acquisition of MorphoSys

Updated Covid vaccine has 54% effectiveness, new study suggests

A protest over insulin prices is seen as a fight for life

Bernie brings in new pharma CEOs to talk drug prices

Medicare Advantage plans can’t deny care with AI, CMS warns

Bernie brings in new pharma CEOs to talk drug prices

focus

entertainment

hotspot

Alkermes shareholders re

Top private equity targets in 2023: cardiology, clinical trials, lasers

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Adopting new red light myopia treatments may be short

Jerome Adams on the need for new antivirals for Covid

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Medical records are filled with copy

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Continuity nursing helped my family in our darkest PICU moments

340B reform proposal comes out of Senate working group

explore

Surgery pushed Ben Carson to fame

AstraZeneca stays mum on Medicare drug pricing negotiations

What’s missing from the debate over nursing home staff minimums

Texas Medical Board asked to define abortion emergency exception

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Adopting new red light myopia treatments may be short

focus

entertainment

focus

Wikipedia